Phase 4 N=302 Clopidogrel and Aspirin Interaction Study-2
Drug Action Increased
Primary: Blood Concentration of the Active Metabolite of Clopidogrel — 14.45; 13.80 ng/ml — p=0.66
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=282 Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
Acute Coronary Syndrome
Primary: Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation 6 Hours After Prasugrel Loading Dose (LD) — 57.86; 35.61; 53.92 PRU — p=0.188
Phase 1 N=20 PPI and Clopidogrel Response
Drug Interaction
Primary: Platelet Function as Assessed by the P2Y12 Reactivity Index — 56.1; 61.6; 56; 61 Percentage of platelet reactivity index
N/A N=18 Clopidogrel Pharmacogenetics (PGX) Bench to Bedside
Metabolism of Clopidogrel
Primary: Change in Platelet Aggregation Following Therapy With Clopidogrel — 62.9; 68.1; 62.5; 63.2 percentage of aggregation
Phase 2 N=50 Clopidogrel Pharmacogenomics Project
Disease Susceptibility
Primary: Clopidogrel Resistance, Defined by P2Y12 Reaction Units (PRU)Value >230 — 30; 18 Number of Patients with PRU>230 — p==0.02
Phase 4 N=15 Antithrombotic Effects of Ticagrelor Versus Clopidogrel
Acute Coronary Syndrome
Primary: Platelet-thrombus Formation in an ex Vivo Model of Thrombosis — 56.3; 35.2 percent change
Phase 4 N=42 Clopidogrel Versus Ticagrelor in Type-2 Diabetes
Coronary Artery Disease · Diabetes Mellitus
Primary: Flow-mediated Dilation of the Brachial Artery — 16.6; 11.6 FMD (%)
Phase 3 N=13,608 A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
Coronary Arteriosclerosis · Acute Coronary Syndromes
Primary: Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke — 469; 565; 174; 216…
Phase 4 N=5,276 Tailored Antiplatelet Therapy Following PCI
Coronary Artery Disease · Acute Coronary Syndrome · Stenosis
Primary: Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. — 35; 54 Participants
Phase 4 N=80 Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease
Coronary Artery Disease
Primary: Platelet Reactivity Unit — 177; 164; 174; 26 PRU — p=>0.05
N/A N=504 Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)
Coronary Artery Disease
Primary: Number of Participants Who Were Responders or Low-Responders of Antiplatelet Therapy as a Result of Whole Blood Aggregometry Testing (See Outcome Measure Description)…
Phase 4 N=81 Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Coronary Artery Disease
Primary: Platelet Reactivity Measured as PRU — 154.5; 23; 104 PRU
N/A N=27 The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization
Coronary Artery Disease · Chest Pain
Primary: The Percentage of Coated Platelets After the Administration of Clopidogrel in Patients Undergoing Cardiac Catheterization and/or Angioplasty — 32.8 Percent of platelets…
Phase 2 N=98 A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
Stable Coronary Artery Disease
Primary: Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus…
Phase 3 N=25,086 Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
Acute Coronary Disease · Angina Unstable
Primary: First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison — 557; 522; 222; 226 participants — p=0.3037
Phase 3 N=18,624 A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke — 864; 1014 Participants
Phase 2 N=139 Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event
Coronary Arteriosclerosis · Acute Coronary Syndrome
Primary: Maximum Platelet Aggregation (MPA) to 20 Micromolar (uM) Adenosine Diphosphase (ADP) — 41.1; 55.0; 41.0 percent maximum platelet aggregation (%) — p=<0.0001
Phase 2 N=123 A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin
Coronary Artery Disease
Primary: Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose — 93.15; 31.05 Percentage
Phase 1 N=84 Clopidogrel Bioequivalence Study in Healthy Subjects
Bioequivalence, AUC, Cmax, Pharmacokinetics
Primary: Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf)) — 1.05; 0.992; 1.09 ng*h/mL
Phase 4 N=37 Antiplatelet Therapy After Cardiac Arrest
Cardiac Arrest · Postresuscitation Syndrome · Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)
Primary: VerifyNow P2Y12Test - Platelet Reactivity — 238; 101 PRU
Phase 4 N=52 Pharmacological Effects of Crushing Prasugrel in STEMI Patients
Coronary Artery Disease
Primary: P2Y12 Reaction Units (PRU) — 95; 164 PRU — p=0.022
Phase 3 N=130 Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
ST Elevation Myocardial Infarction · NSTEMI - Non-ST Segment Elevation MI
Primary: Evaluation of Platelet Inhibition — 94; 141 P2Y12 Reaction Units (PRU)
Phase 3 N=906 Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation
Heart Defects, Congenital
Primary: Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature)…
Phase 4 N=24 Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Coronary Artery Disease
Primary: Change From Baseline in ADP-mediated Platelet Aggregation, APP, SFFLRN, AYPGKF. — 84; 38; 94; 53 % inhibitn of platelet aggregation — p=0.001
Phase 2 N=15 Anti-Platelets in Chronic Obstructive Pulmonary Disease
COPD · Emphysema · Emphysema or COPD
Primary: Pulmonary Microvascular Blood Volume, CV — 0.89; 0.88; 0.92; 0.91 CV — p=0.84
Phase 4 N=98 Clopidogrel Monotherapy in Patients With High Bleeding Risk
Bleeding Complications
Primary: Ischemic Risk Post-PCI in High Bleed Risk Patients With Genotype-guided Single Antiplatelet Therapy — 0; 1 Participants
Phase 2 N=15 Cangrelor to Clopidogrel or Prasugrel Transition Study
Coronary Artery Disease (CAD)
Primary: Extent of Preservation Of Platelet Inhibitory Effect After Transition From Cangrelor To Prasugrel Or Clopidogrel Compared With Effect Observed With Prasugrel Or…
Phase 3 N=719 A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-mediated Platelet Aggregation (P2Y12 Reaction Units; PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 4 Hours…
Phase 4 N=20 Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients
Type-2 Diabetes Mellitus · Coronary Artery Disease
Primary: Thrombus Formation — 66.9; 84.4; 59.9; 79.8 percentage of baseline size
Phase 3 N=7,554 Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
Atrial Fibrillation · Vascular Risk
Primary: First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per…